Welcome to our dedicated page for NERVGEN PHARMA SEC filings (Ticker: NGENF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
NervGen Pharma Corp. filings document a Canadian clinical-stage biotechnology issuer furnishing U.S. reports as a foreign issuer. The record includes Form 6-K current reports, material change reports, and incorporation by reference into the company’s MJDS Form F-10 registration statement.
The company’s SEC disclosures cover executive appointments and resignations, employment agreements, stock option grants, board oversight, subsidiary employment arrangements through NervGen US Inc., and capital-market registration matters. These filings also provide formal records tied to governance, compensation, equity awards, and the company’s U.S. public reporting framework.
NervGen Pharma Corp. has filed Amendment No. 1 to a Form F-10 registration statement linked to an amended and restated Canadian short form base shelf prospectus covering up to U.S.$150,000,000 of securities. Over a 25‑month period, the company and certain securityholders may sell common shares, debt securities, subscription receipts, warrants and units in various combinations, including potential at‑the‑market distributions, with exact terms set in future prospectus supplements. NervGen is a clinical‑stage biopharmaceutical company developing neuroreparative therapies, led by NVG‑291 for spinal cord injury, and currently has no approved products or product revenue. The prospectus notes plans to list common shares on the Nasdaq Capital Market under the symbol “NGEN”, while they remain listed on the TSX‑V and OTCQB. Extensive risk disclosures highlight ongoing losses, the need for additional capital, clinical and regulatory uncertainty, and cross‑border enforcement and disclosure differences for U.S. investors.